Structural and functional neuroimaging in amyotrophic lateral sclerosis by Ilya S. Bakulin, Aleksandr V. Chervyakov, Elena I. Kremneva, Rodion N. Konovalov, Maria N. Zakharova

Subjects: “…amyotrophic lateral sclerosis…”
Get full text

Place of death in patients with amyotrophic lateral sclerosis by J. Escarrabill, A. Vianello, E. Farrero, N. Ambrosino, J. Martínez Llorens, M. Vitacca

“…Amyotrophic lateral sclerosis (ALS) is a degenerative neurological disorder that affects motor neurons. …”
Get full text

Dihydrotestosterone in Amyotrophic lateral sclerosis—The missing link? by Nishit Sawal, Jasbinder Kaur, Kamaljeet Kaur, Satinder Gombar

Subjects: “…Amyotrophic Lateral Sclerosis…”
Get full text

Staging model for amyotrophic lateral sclerosis in Singapore by Yuan Teck Tay, Josiah YH Chai, Kamilah Bte Shekh Jabin, Kexin Ang

Subjects: “…amyotrophic lateral sclerosis…”
Get full text

Invertebrate genetic models of amyotrophic lateral sclerosis by LiJun Zhou, LiJun Zhou, RenShi Xu, RenShi Xu

Subjects: “…amyotrophic lateral sclerosis…”
Get full text

Potential Preventive Strategies for Amyotrophic Lateral Sclerosis by B. Kuraszkiewicz, H. Goszczyńska, T. Podsiadły-Marczykowska, M. Piotrkiewicz, P. Andersen, M. Gromicho, J. Grosskreutz, J. Grosskreutz, M. Kuźma-Kozakiewicz, S. Petri, B. Stubbendorf, K. Szacka, H. Uysal, M. de Carvalho

Subjects: “…amyotrophic lateral sclerosis…”
Get full text

Imaging Cerebral Activity in Amyotrophic Lateral Sclerosis by Malcolm Proudfoot, Peter Bede, Martin R. Turner, Martin R. Turner

Subjects: “…amyotrophic lateral sclerosis…”
Get full text

Diagnostic criteria of amyotrophic lateral sclerosis (ALS) by Reinhard Dengler

Subjects: “…amyotrophic lateral sclerosis…”
Get full text

Quantitative FLAIR MRI in amyotrophic lateral sclerosis by Fabes, J, Matthews, L, Filippini, N, Talbot, K, Jenkinson, M, Turner, M

“…<strong>Rationale and Objectives</strong> T2-weighted MRI hyperintensity assessed visually in the corticospinal tract (CST) lacks sensitivity for a diagnosis of amyotrophic lateral sclerosis (ALS). We sought to explore a quantitative approach to FLAIR MRI intensity across a range of ALS phenotypes. …”

Biomarkers in amyotrophic lateral sclerosis: opportunities and limitations. by Bowser, R, Turner, M, Shefner, J

“…Insights into the mechanisms of amyotrophic lateral sclerosis (ALS) have relied predominantly on the study of postmortem tissue. …”

Inflammation and neurovascular changes in amyotrophic lateral sclerosis by Evans, M, Couch, Y, Sibson, N, Turner, MR

“…Neuroinflammation in now established as an important factor in the pathogenesis of many neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). At various time points, astrocytes and microglia are markedly activated, either producing neuroprotective or pro-inflammatory molecules, which can decrease or increase the rate of primary motor neuron degeneration respectively. …”

The tough body at the epicentre of amyotrophic lateral sclerosis by Turner, M, Menke, R

Sweet food preference in amyotrophic lateral sclerosis by Turner, M, Talbot, K

“…Although tongue electromyography (EMG) was normal, corticobulbar signs were consistent with amyotrophic lateral sclerosis (ALS), a pattern which in the absence of functional impairment outside of speech and swallowing, is appropriately termed progressive bulbar palsy…”

Inflammation and neurovascular changes in amyotrophic lateral sclerosis. by Evans, M, Couch, Y, Sibson, N, Turner, M

“…Neuroinflammation in now established as an important factor in the pathogenesis of many neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). At various time points, astrocytes and microglia are markedly activated, either producing neuroprotective or pro-inflammatory molecules, which can decrease or increase the rate of primary motor neuron degeneration respectively. …”

Defining pre-symptomatic amyotrophic lateral sclerosis by Benatar, M, Turner, M, Wuu, J

“…This requires an understanding of early/pre-symptomatic disease, a need that is underscored by advances in antisense oligonucleotide, and viral-vector-based gene therapies. In amyotrophic lateral sclerosis (ALS), the study of pre-symptomatic disease requires a cohesive conceptual framework for describing this phase of disease. …”

Quantifying disease progression in amyotrophic lateral sclerosis. by Simon, N, Turner, M, Vucic, S, Al-Chalabi, A, Shefner, J, Lomen-Hoerth, C, Kiernan, M

“…Amyotrophic lateral sclerosis (ALS) exhibits characteristic variability of onset and rate of disease progression, with inherent clinical heterogeneity making disease quantitation difficult. …”

CSF chitinase proteins in amyotrophic lateral sclerosis by Thompson, A, Gray, E, Bampton, A, Raciborska, D, Talbot, K, Turner, M

“…<p>Objective: To evaluate the classifier performance, clinical and biochemical correlations of cerebrospinal fluid (CSF) levels of the chitinase proteins Chitotriosidase-1 (CHIT1), Chitinase-3-like protein 1 (CHI3L1) and Chitinase-3-like protein 2 (CHI3L2) in amyotrophic lateral sclerosis (ALS).</p> <p>Methods: CSF levels of CHIT1, CHI3L1, CHI3L2, phosphorylated neurofilament heavy chain (pNFH) and C-reactive protein were measured by ELISA in a longitudinal cohort of patients with ALS (n=82), primary lateral sclerosis (PLS, n=10), ALS-mimic conditions (n=12), healthy controls (n=25) and asymptomatic carriers of ALS-causing genetic mutations (AGC; n=5).…”

Defective cholesterol metabolism in amyotrophic lateral sclerosis. by Abdel-Khalik, J, Yutuc, E, Crick, P, Gustafsson, J, Warner, M, Roman, G, Talbot, K, Gray, E, Griffiths, W, Turner, M, Wang, Y

“…As neurons die cholesterol is released in the central nervous system (CNS), hence this sterol and its metabolites may represent a biomarker of neurodegeneration, including in amyotrophic lateral sclerosis (ALS) in which altered cholesterol levels have been linked to prognosis. …”

Imaging cerebral activity in amyotrophic lateral sclerosis by Proudfoot, M, Bede, P, Turner, M

“…Advances in neuroimaging, complementing histopathological insights, have established a multi-system involvement of cerebral networks beyond the traditional neuromuscular pathological view of amyotrophic lateral sclerosis (ALS). The development of effective disease-modifying therapy remains a priority and this will be facilitated by improved biomarkers of motor system integrity against which to assess the efficacy of candidate drugs. …”

Psychiatric disorders prior to amyotrophic lateral sclerosis by Turner, M, Goldacre, R, Talbot, K, Goldacre, M